Objective: The present study aimed at evaluating the acute effect of increasing doses of octreotide (OCT), a long-acting somatostatin analogue, on glucose tolerance and insulin secretion. Methods: A standard and two other oral glucose tolerance tests 30 min after subcutaneous administration of OCT were performed in randomized order in each subject. Obese subjects received 10, 25, or 50 µg of OCT; control subjects received only 10 and 25 µg. Fifteen obese and 10 control subjects were studied; all of them had a normal glucose tolerance. Plasma glucose and insulin levels were measured at times –30, 0, 30, 60, 90, 120, 150, and 180 min after the glucose tolerance test. Results: The results demonstrated that, following OCT administration, both control and obese subjects developed a reduced glucose tolerance, a delayed glycemic peak, and an increase of late plasma glucose values. Fasting as well as stimulated insulin secretions were higher in obese subjects as compared with controls, and insulin secretion was inhibited in a dose-dependent manner by OCT. Conclusions: These data indicate that the action of OCT might be due to at least two different cooperative mechanisms: (1) a delayed glucose absorption, as suggested by the delay of glycemic peak, and (2) a direct or vagal-mediated effect on β-cells, as suggested by the reduction of the area under the curve values in spite of the elevated late glycemic levels. It is noteworthy that doses of OCT as low as 10 and 25 µg are sufficient to inhibit insulin secretion both in normal and obese subjects.

1.
Patel YC, Orci L, Dankier A, Cameron DP: Decreased pancreatic somatostatin concentration in spontaneously diabetic mice. Endocrinology 1976;99:1415–1418.
2.
Carlsson P-O, Jansson L: The long-acting somatostatin analogue octreotide decreases pancreatic islet blood flow in rats. Pancreas 1994;9:361–364.
3.
Li Y, Owyang C: Somatostatin inhibits pancreatic enzyme secretion at a central vagal site. Am J Physiol 1993;265:G251–G257.
4.
Schudziarra V, Lawecki J, Ditschuneit HH, Lukas B, Maier V, Pfeiffer EF: Effect of low-dose somatostatin infusion on pancreatic and gastric endocrine function in lean and obese nondiabetic human subjects. Diabetes 1985;34:595–601.
5.
Schudziarra V: Physiological significance of gastrointestinal somatostatin. Horm Res 1988;29:75–78.
6.
Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321–1325.
7.
Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hssr 1-5). Endocrinology 1994;135:2814–2817.
8.
Davies RR, Miller M, Turner SJ, Goodship THJ, Cook DB, Watson M, McGill A, Orksov H, Alberti KGMM, Johnston DG: Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol (Oxf) 1986;24:665–674.
9.
Giustina A, Bussi AR, Pizzocolo G, Cimino A, Giustina G: Acute effects of octreotide, a long-acting somatostatin analogue, on the insulinemic and glycemic responses to a mixed meal in patients with essential obesity: A dose-response study. Diabetes Nutr Metab 1994;7:35–41.
10.
WHO Expert Committee on Diabetes Mellitus: Second Report. WHO Tech Rep Ser No 646. Geneva, WHO, 1980.
11.
Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992;89:251–255.
12.
Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC: Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann NY Acad Sci 1994;733:122–137.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.